Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million
individuals and is responsible for over 1.7 million deaths to date. Infection is associated with the …

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers
who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against …

Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …

During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory
syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and …

Neutralizing antibody responses to coronaviruses mainly target the receptor-binding
domain (RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different antibody …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes
coronavirus disease 2019 (COVID-19), primarily infects cells at mucosal surfaces. Serum …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell
responses that continue to evolve for at least a year. During that time, memory B cells express …

Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of
clinical concern. In a cohort of 417 persons who had received the second dose of …